Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 4, 2025
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
GlobeNewswire
·
August 4, 2025
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a …
iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market
GlobeNewswire
·
August 4, 2025
WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers …
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence
GlobeNewswire
·
August 4, 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) reschedules its earnings release and conference call for the quarterly period ended June 30, 2025, to finalize its Fresh Start …
Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger
GlobeNewswire
·
August 4, 2025
Atlanta, GA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) and SunLink Health Systems, Inc. (“SunLink”) (NYSE American: SSY) jointly announced today that, at special meetings of their …
Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results
GlobeNewswire
·
August 4, 2025
EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, …
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 4, 2025
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement awards to Anshul Thakral, the Company’s recently …
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 4, 2025
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 4, 2025
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease
GlobeNewswire
·
August 4, 2025
New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased specialty care, and meaningful reductions in …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
GlobeNewswire
·
August 4, 2025
LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted …
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
GlobeNewswire
·
August 4, 2025
Cellectis to host an Investor R…
Cellectis publie ses résultats financiers du deuxième trimestre 2025 et une mise à jour de ses activités
GlobeNewswire
·
August 4, 2025
Cellectis organise un R…
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
GlobeNewswire
·
August 4, 2025
HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the …
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 4, 2025
-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for …
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
GlobeNewswire
·
August 4, 2025
Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7% U.S. revenue of $46.4 million, representing growth of 22.8% Gross margin of 79.8%, representing an …
Ardelyx Announces Changes to the Executive Leadership Team
GlobeNewswire
·
August 4, 2025
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- …
CVRx Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 4, 2025
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …
Castle Biosciences Reports Second Quarter 2025 Results
GlobeNewswire
·
August 4, 2025
Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million …
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
August 4, 2025
FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases …
Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 4, 2025
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the …